Name | Title | Contact Details |
---|
At Signature Health, we treat the mind and body with an integrated approach to health care. We offer mental health, primary care, and addiction recovery services.
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
Eddingpharm Group Co. is a Carrboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Merz Pharmaceuticals is an innovative pharmaceutical company specializing in the research and marketing of drugs for the treatment of